Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WCCS 2016 /
Treatment of cutaneous T cell lymphoma

31st Aug - 3rd Sep 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.09.16
Views: 1505

Dr Madeleine Duvic - Anderson Cancer Center, Houston, USA

Dr Duvic speaks with ecancertv at WCCS 2016 about mogamulizumab, an anti-CCR4 engineered antibody for treatment of cutaneous T cell lymphoma, also known as Sézary syndrome

She reports on results from a phase I/II trial in which patient response rate reached 37%, and describes upcoming trials for mogamulizumab, with considerations of international approval and possible combination/complementary therapies. 

ecancer's filming at WCCS 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation